Literature DB >> 25789705

Ruxolitinib Attenuates Cutaneous Lupus Development in a Mouse Lupus Model.

Emilie S Chan1, Leal C Herlitz2, Ali Jabbari3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25789705     DOI： 10.1038/jid.2015.107

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  20 in total

1.  Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice.

Authors:  Déborah Braun; Pedro Geraldes; Jocelyne Demengeot
Journal:  J Autoimmun       Date:  2003-02       Impact factor: 7.094

Review 2.  Mechanisms of type-I- and type-II-interferon-mediated signalling.

Authors:  Leonidas C Platanias
Journal:  Nat Rev Immunol       Date:  2005-05       Impact factor: 53.106

3.  Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation.

Authors:  Jordan S Fridman; Peggy A Scherle; Robert Collins; Timothy Burn; Claire L Neilan; Denise Hertel; Nancy Contel; Patrick Haley; Beth Thomas; Jack Shi; Paul Collier; James D Rodgers; Stacey Shepard; Brian Metcalf; Gregory Hollis; Robert C Newton; Swamy Yeleswaram; Steven M Friedman; Kris Vaddi
Journal:  J Invest Dermatol       Date:  2011-06-16       Impact factor: 8.551

4.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

5.  Dermatopathological studies on skin lesions of MRL mice.

Authors:  F Furukawa; H Tanaka; K Sekita; T Nakamura; Y Horiguchi; Y Hamashima
Journal:  Arch Dermatol Res       Date:  1984       Impact factor: 3.017

Review 6.  Immunology of psoriasis.

Authors:  Michelle A Lowes; Mayte Suárez-Fariñas; James G Krueger
Journal:  Annu Rev Immunol       Date:  2014       Impact factor: 28.527

7.  Type I IFN protects against murine lupus.

Authors:  Jonathan D Hron; Stanford L Peng
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

8.  The role of IL-23/IL-17 axis in lupus nephritis.

Authors:  Zheng Zhang; Vasileios C Kyttaris; George C Tsokos
Journal:  J Immunol       Date:  2009-08-05       Impact factor: 5.422

9.  In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon.

Authors:  C O Jacob; P H van der Meide; H O McDevitt
Journal:  J Exp Med       Date:  1987-09-01       Impact factor: 14.307

10.  Dominant Th1 and minimal Th17 skewing in discoid lupus revealed by transcriptomic comparison with psoriasis.

Authors:  Ali Jabbari; Mayte Suárez-Fariñas; Judilyn Fuentes-Duculan; Juana Gonzalez; Inna Cueto; Andrew G Franks; James G Krueger
Journal:  J Invest Dermatol       Date:  2013-06-14       Impact factor: 8.551
View more
  10 in total

Review 1.  Interferon-directed therapies for the treatment of systemic lupus erythematosus: a critical update.

Authors:  Yashaar Chaichian; Vibeke Strand
Journal:  Clin Rheumatol       Date:  2021-01-07       Impact factor: 2.980

Review 2.  Lupus erythematosus revisited.

Authors:  Annegret Kuhn; Joerg Wenzel; Marc Bijl
Journal:  Semin Immunopathol       Date:  2015-12-04       Impact factor: 11.759

Review 3.  Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.

Authors:  Alessia Alunno; Ivan Padjen; Antonis Fanouriakis; Dimitrios T Boumpas
Journal:  Cells       Date:  2019-08-15       Impact factor: 6.600

Review 4.  Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases.

Authors:  Kata P Szilveszter; Tamás Németh; Attila Mócsai
Journal:  Front Immunol       Date:  2019-08-09       Impact factor: 7.561

Review 5.  Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus.

Authors:  I-Tsu Chyuan; Hong-Tai Tzeng; Ji-Yih Chen
Journal:  Cells       Date:  2019-08-23       Impact factor: 6.600

6.  Shared inflammatory and skin-specific gene signatures reveal common drivers of discoid lupus erythematosus in canines, humans and mice.

Authors:  Colton J Garelli; Neil B Wong; Cesar Piedra-Mora; Linda M Wrijil; Gina Scarglia; Clement N David; Ramón M Almela; Nicholas A Robinson; Jillian M Richmond
Journal:  Curr Res Immunol       Date:  2021-03-31

Review 7.  Jak Inhibitors for Treatment of Autoimmune Diseases: Lessons from Systemic Sclerosis and Systemic Lupus Erythematosus.

Authors:  Przemysław Kotyla; Olga Gumkowska-Sroka; Bartosz Wnuk; Kacper Kotyla
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-28

8.  Treatment of cutaneous lupus with topical ruxolitinib cream.

Authors:  Jonathan J Park; Alicia J Little; Matthew D Vesely
Journal:  JAAD Case Rep       Date:  2022-08-28

Review 9.  Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?

Authors:  Patricia Richter; Anca Cardoneanu; Alexandra Maria Burlui; Luana Andreea Macovei; Ioana Bratoiu; Oana Nicoleta Buliga-Finis; Elena Rezus
Journal:  Int J Mol Sci       Date:  2022-10-04       Impact factor: 6.208

10.  Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions.

Authors:  Tanja Fetter; Paul Smith; Tugce Guel; Christine Braegelmann; Thomas Bieber; Joerg Wenzel
Journal:  Front Immunol       Date:  2020-03-03       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.